Truist analyst David MacDonald raised The Pennant Group’s price target to $36[1] from $34[1] and kept a Buy rating on April 13[1].
The upgrade matters because price targets influence institutional and retail investors’ valuation models. A higher target can broaden the stock’s appeal, potentially increasing liquidity and supporting a stronger share price. In a sector where many providers face reimbursement pressure, a Buy rating from a major bank signals confidence in the company’s earnings trajectory[1].
Pennant Group, a U.S.-based provider of home‑health services, has benefited from steady demand for in‑home care, a trend MacDonald said is unlikely to reverse. The aging U.S. population and a preference for receiving medical assistance at home have kept enrollment numbers solid. MacDonald said upcoming Medicare rule changes slated for 2026 will relax certain home‑health restrictions, further supporting the company’s growth outlook[1].
The company reported Q4 2025 revenue of $289.32 million[4], a 53.2% increase year over year[4], while earnings per share rose to $0.34[4] from $0.24[4] a year earlier. The revenue jump reflects higher utilization of the firm’s skilled nursing and therapy services, and the EPS improvement shows better cost control and margin expansion[4].
MacDonald said the combination of stable demand and the easing Medicare regulations justifies keeping a Buy rating and suggests the stock has continued upside potential.
MacDonald said the new price target of $36[1] represents a modest premium over the current trading range, giving investors room for upside while acknowledging valuation discipline[1].
Analysts who follow Truist’s research said the new target aligns with the firm’s broader expectation that home‑health providers will outperform the broader healthcare sector as the population ages.
**What this means** The raised target signals Truist’s confidence that Pennant Group can sustain rapid revenue growth amid favorable regulatory changes. Investors may view the upgrade as validation of the company’s business model, potentially prompting buying interest that could lift the stock toward the $36 level. At the same time, the modest premium suggests analysts still see valuation discipline, meaning upside may be incremental rather than explosive.
“Truist raised its price target to $36.”
Truist’s higher price target underscores confidence in Pennant Group’s ability to capitalize on aging‑population trends and looser Medicare rules, which may attract investors and modestly boost the share price.
